A Phase 1/2 interventional study of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) and 7-Valent Pneumococcal Conjugate Vaccine (7vPnC) in Healthy Subjects and Pneumococcal Infections, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 1 site in United States. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-15.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 27th largest by enrollment, is the only one that started in 2004, is the only one in phase 1/2, and was the 1st registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →
13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 42 Days to 98 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 20 · Phase 4 11
First in 2004; this study’s year is marked. 1 started in 2004.
This study's enrollment of 249 is below the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 328 across the 44 interventional studies. Of the 40 that completed or were terminated, 23 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Wyeth is now a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 46th largest by enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2004, is one of 2 in phase 1/2, and was the 3rd registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and immunogenicity of the 13-valent pneumococcal conjugate vaccine (13vPnC) in healthy infants. This is the first study with this vaccine in infants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)
Biological: 7-Valent Pneumococcal Conjugate Vaccine (7vPnC)
Percentage of Participants Reporting Pre-Specified Local Reactions
Local reaction events were collected using a paper worksheet. Tenderness was scaled as Any (tenderness present); Significant (Sig.) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod.)(2.5 to 7.0 cm); Severe (Sev.)(\> 7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 15 days after each dose
Percentage of Participants Reporting Pre-Specified Systemic Events
Systemic events (fever \[Fv\] ≥ 38 degrees Celsius \[C\] but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased (decr.) appetite, irritability, increased sleep, decreased sleep, use of medication (Med.)to prevent symptoms (sx), and use of medication to treat symptoms) were reported using a paper worksheet. Participants may be represented in more than 1 category.
Time frame: Within 15 days after each dose
Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series
Percentage of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
Time frame: one month after 3-dose infant series (at 7 months of age)
Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
Time frame: One month after the toddler dose (at 13 to 16 months of age)
Geometric Mean Antibody Concentration in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series
Antibody geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC ratios (13vPnC/7vPnC) and corresponding 2-sided 95% CI were evaluated.
Time frame: One month after 3-dose infant series (at 7 months of age)
Geometric Mean Concentration in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose
Antibody geometric mean concentration (GMC) as measured by ELISA with their corresponding 95% CI immediately before and after the toddler dose for 7 common pneumococcal serotypes (Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: Immediately before (12 to 15 months of age) and one month after the toddler dose (13 to 16 months of age)
Percentage of Participants Achieving Predefined Antibody Levels for Haemophilus Influenzae Type b, Diphtheria Toxoid, Polio, Pertussis, Tetanus, and Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series
Percentage of participants achieving predefined antibody threshold levels for Haemophilus Influenzae Type b (Hib) polyribosylribitol phosphate (PRP), Diphtheria Toxoid, Polio (Types 1, 2, and 3), Pertussis (filamentous hemagglutinin \[FHA\], Pertussis Toxoid, and Pertactin), Tetanus, and Hepatitis B with the corresponding 95% CI for each concomitant antigen are presented.
Time frame: One month after the infant series (7 months of age)
Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the Infant Series
Time frame: one month after the infant series (7 months of age)
Geometric Mean Antibody Concentration of Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series
GMCs of anti-hepatitis B surface antigen (HBsAg) using a Food and Drug Administration (FDA) approved in vitro diagnostic kit are presented.
Time frame: one month after the infant series (7 months of age)
Geometric Mean Antibody Concentration Diphtheria Toxoid and Anti-Tetanus Toxoid in 13vPnC Group Relative to 7vPnC Group After the Infant Series
Time frame: one month after the infant series (7 months of age)
Geometric Mean Antibody Concentration of Polio in 13vPnC Group Relative to 7vPnC Group After the Infant Series
Time frame: one month after the infant series (7 months of age)
Geometric Mean Antibody Concentration of Pertussis Antigens in 13vPnC Group Relative to 7vPnC Group After the Infant Series
Time frame: one month after the infant series (7 months of age)
Percentage of Participants Achieving Antibody Titer (OPA) ≥1:8 in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series
Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: one month after the infant series (7 months of age)
Percentage of Participants Achieving Antibody Titer (OPA) ≥1:8 in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were assessed. Results are reported for the serotypes with a determinate antibody titer.
Time frame: One month after the toddler dose (13 to 16 months of age)
Geometric Mean Antibody Titer (OPA) in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay (OPA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were assessed. Results are reported for the serotypes with a determinate antibody titer.
Time frame: One month after the Toddler Dose (13 to 16 months of age)
Participants were recruited in the United States from September 2004 to September 2005.
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 122 | 127 |
| Vaccinated dose 1 | 121 | 126 |
| Vaccinated dose 2 | 115 | 122 |
| Vaccinated dose 3 | 110 | 118 |
| Completed | 104 | 116 |
| Not completed | 18 | 11 |
| Withdrew: Lost to follow-up | 10 | 4 |
| Withdrew: Withdrawal by subject | 2 | 5 |
| Withdrew: Physician decision | 3 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lost kaiser coverage | 0 | 1 |
| Withdrew: Non-compliant | 1 | 0 |
| Withdrew: Sponsor request | 1 | 0 |
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 104 | 116 |
| Completed | 86 | 103 |
| Not completed | 18 | 13 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Physician decision | 3 | 2 |
| Withdrew: Withdrawal by subject | 1 | 4 |
| Withdrew: Other | 10 | 4 |
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 86 | 103 |
| Completed | 84 | 100 |
| Not completed | 2 | 3 |
| Withdrew: Lost to follow-up | 2 | 3 |
Local reaction events were collected using a paper worksheet. Tenderness was scaled as Any (tenderness present); Significant (Sig.) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod.)(2.5 to 7.0 cm); Severe (Sev.)(\> 7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Dose 1 | 7vPnc Dose 1 | 13vPnC Dose 2 | 7vPnC Dose 2 | 13vPnC Dose 3 | 7vPnC Dose 3 | 13vPnC Toddler Dose | 7vPnC Toddler Dose |
|---|---|---|---|---|---|---|---|---|
| Tenderness-Any (n=119,124,110,118,107,117,85,101) | 34.5 | 43.5 | 28.2 | 36.4 | 24.3 | 25.6 | 22.4 | 29.7 |
| Tenderness-Sig. (n=119,124,110,118,107,117,85,101) | 8.4 | 5.6 | 1.8 | 8.5 | 4.7 | 6.0 | 2.4 | 4.0 |
| Induration-Any (n=119,124,110,118,107,117,85,100) | 21.8 | 19.4 | 16.4 | 19.5 | 16.8 | 18.8 | 18.8 | 17.0 |
| Induration-Mild (n=119,123,110,117,107,116,85,100) | 20.2 | 17.9 | 16.4 | 17.1 | 16.8 | 17.2 | 18.8 | 17.0 |
| Induration-Mod. (n=119,123,110,117,107,116,85,100) | 3.4 | 2.4 | 3.6 | 3.4 | 0.0 | 4.3 | 2.4 | 3.0 |
| Induration-Sev. (n=119,123,110,117,107,116,85,100) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Erythema-Any (n=119,124,111,118,107,117, 85,100) | 21.0 | 19.4 | 16.2 | 17.8 | 17.8 | 19.7 | 24.7 | 19.0 |
| Erythema-Mild (n=119,124,110,117,106,116,85,99) | 20.2 | 19.4 | 13.6 | 17.1 | 16.0 | 18.1 | 24.7 | 16.2 |
| Erythema-Mod. (n=119,124,108,117,106,116,85,99) | 2.5 | 0.0 | 2.8 | 0.0 | 0.9 | 2.6 | 3.5 | 5.1 |
| Erythema-Severe (n=119,124,108,117,106,116,85,99) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Systemic events (fever \[Fv\] ≥ 38 degrees Celsius \[C\] but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased (decr.) appetite, irritability, increased sleep, decreased sleep, use of medication (Med.)to prevent symptoms (sx), and use of medication to treat symptoms) were reported using a paper worksheet. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Dose 1 | 7vPnc Dose 1 | 13vPnC Dose 2 | 7vPnC Dose 2 | 13vPnC Dose 3 | 7vPnC Dose 3 | 13vPnC Toddler Dose | 7vPnC Toddler Dose |
|---|---|---|---|---|---|---|---|---|
| Fv ≥38°C but≤39°C(n=114,121,102,114,100,113,78,94) | 16.7 | 16.5 | 21.6 | 24.6 | 20.0 | 20.4 | 14.1 | 12.8 |
| Fv >39°C but≤40°C(n=113,121,102,113,101,113,77,94) | 2.7 | 0.8 | 3.9 | 3.5 | 2.0 | 0.9 | 2.6 | 0.0 |
| Fv >40°C (n=113,121,102,113,100,113,76,94) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Decr. Appetite (n=118,124,110,118,107,117,85,101) | 30.5 | 31.5 | 22.7 | 22.9 | 27.1 | 30.8 | 22.4 | 21.8 |
| Decr. Sleep (n=118,124,110,118,107,117,84,101) | 18.6 | 17.7 | 24.5 | 19.5 | 21.5 | 18.8 | 13.1 | 14.9 |
| Increased Sleep (n=119,124,111,118,107,117,86,101) | 56.3 | 54.0 | 42.3 | 46.6 | 34.6 | 41.0 | 27.9 | 43.6 |
| Irritability (n=118,124,110,118,107,117,85,101) | 66.9 | 71.0 | 62.7 | 56.8 | 51.4 | 53.8 | 38.8 | 47.5 |
| Med.-Prevent Sx (n=95,101,86,96,83,93,85,102) | 29.5 | 33.7 | 34.9 | 32.3 | 36.1 | 43.0 | 17.6 | 35.3 |
| Med.-Treat Symptoms (n=94,101,86,96,84,94,85,101) | 44.7 | 34.7 | 48.8 | 50.0 | 42.9 | 47.9 | 29.4 | 27.7 |
Percentage of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Common Serotypes - Serotype 4 (n=94,107) | 96.81 (90.96 to 99.34) | 99.07 (94.90 to 99.98) |
| Common Serotypes - Serotype 6B (n=94,107) | 88.30 (80.03 to 94.01) | 88.79 (81.23 to 94.07) |
| Common Serotypes - Serotype 9V (n=94,108) | 96.81 (90.96 to 99.34) | 99.07 (94.95 to 99.98) |
| Common Serotypes - Serotype 14 (n=94,107) | 97.87 (92.52 to 99.74) | 97.20 (92.02 to 99.42) |
| Common Serotypes - Serotype 18C (n=94,106) | 96.81 (90.96 to 99.34) | 99.06 (94.86 to 99.98) |
| Common Serotypes - Serotype 19F (n=94,106) | 97.87 (92.52 to 99.74) | 97.17 (91.95 to 99.41) |
| Common Serotypes - Serotype 23F (n=94,108) | 94.68 (88.02 to 98.25) | 95.37 (89.53 to 98.48) |
| Additional Serotypes - Serotype 1 (n=94,108) | 97.87 (92.52 to 99.74) | 25.00 (17.17 to 34.25) |
| Additional Serotypes - Serotype 3 (n=94,107) | 98.94 (94.21 to 99.97) | 14.02 (8.06 to 22.07) |
| Additional Serotypes - Serotype 5 (n=93,107) | 100.00 (96.11 to 100.00) | 42.06 (32.58 to 51.99) |
| Additional Serotypes - Serotype 6A (n=93,106) | 96.77 (90.86 to 99.33) | 33.96 (25.04 to 43.80) |
| Additional Serotypes - Serotype 7F (n=94,105) | 98.94 (94.21 to 99.97) | 6.67 (2.72 to 13.25) |
| Additional Serotypes - Serotype 19A (n=94,107) | 100.00 (96.15 to 100.00) | 94.39 (88.19 to 97.91) |
Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Common Serotypes - Serotype 4 (n=78,94) | 97.4 (91.0 to 99.7) | 98.9 (94.2 to 100.0) |
| Common Serotypes - Serotype 6B (n=78,93) | 100.0 (95.4 to 100.0) | 100.0 (96.1 to 100.0) |
| Common Serotypes - Serotype 9V (n=78,94) | 98.7 (93.1 to 100.0) | 100.0 (96.2 to 100.0) |
| Common Serotypes - Serotype 14 (n=78,93) | 100.0 (95.4 to 100.0) | 100.0 (96.1 to 100.0) |
| Common Serotypes - Serotype 18C (n=78,94) | 100.0 (95.4 to 100.0) | 100.0 (96.2 to 100.0) |
| Common Serotypes - Serotype 19F (n=78,93) | 100.0 (95.4 to 100.0) | 100.0 (96.1 to 100.0) |
| Common Serotypes - Serotype 23F (n=78,93) | 100.0 (95.4 to 100.0) | 97.8 (92.4 to 99.7) |
| Additional Serotypes - Serotype 1 (n=78,91) | 100.00 (95.4 to 100.00) | 2.2 (0.3 to 7.7) |
| Additional Serotypes - Serotype 3 (n=78,92) | 92.3 (84.0 to 97.1) | 8.7 (3.8 to 16.4) |
| Additional Serotypes - Serotype 5 (n=78,78) | 100.0 (95.4 to 100.0) | 70.5 (59.1 to 80.3) |
| Additional Serotypes - Serotype 6A (n=78,92) | 100.0 (95.4 to 100.0) | 88.0 (79.6 to 93.9) |
| Additional Serotypes - Serotype 7F (n=78,85) | 100.0 (95.4 to 100.0) | 5.9 (1.9 to 13.2) |
| Additional Serotypes - Serotype 19A (n=78,93) | 100.0 (95.4 to 100.0) | 100.0 (96.1 to 100.0) |
Antibody geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC ratios (13vPnC/7vPnC) and corresponding 2-sided 95% CI were evaluated.
| μg/mL | 13vPnC | 7vPnC |
|---|---|---|
| Common Serotypes - Serotype 4 (n=94,107) | 1.81 (1.54 to 2.13) | 2.40 (2.01 to 2.87) |
| Common Serotypes - Serotype 6B (n=94,107) | 2.74 (2.02 to 3.71) | 2.86 (2.09 to 3.91) |
| Common Serotypes - Serotype 9V (n=94,108) | 1.52 (1.29 to 1.78) | 1.78 (1.55 to 2.05) |
| Common Serotypes - Serotype 14 (n=94,107) | 4.24 (3.44 to 5.23) | 5.19 (4.13 to 6.52) |
| Common Serotypes - Serotype 18C (n=94,106) | 1.53 (1.30 to 1.80) | 2.46 (2.08 to 2.91) |
| Common Serotypes - Serotype 19F (n=94,106) | 2.21 (1.87 to 2.61) | 2.58 (2.17 to 3.08) |
| Common Serotypes - Serotype 23F (n=94,108) | 1.39 (1.15 to 1.67) | 1.81 (1.51 to 2.19) |
| Additional Serotypes - Serotype 1 (n=94,108) | 2.57 (2.14 to 3.08) | 0.06 (0.05 to 0.09) |
| Additional Serotypes - Serotype 3 (n=94,107) | 1.40 (1.20 to 1.62) | 0.09 (0.07 to 0.11) |
| Additional Serotypes - Serotype 5 (n=93,107) | 2.41 (2.07 to 2.80) | 0.28 (0.22 to 0.34) |
| Additional Serotypes - Serotype 6A (n=93,106) | 2.36 (1.89 to 2.94) | 0.25 (0.20 to 0.30) |
| Additional Serotypes - Serotype 7F (n=94,105) | 1.85 (1.62 to 2.11) | 0.07 (0.06 to 0.08) |
| Additional Serotypes - Serotype 19A (n=94,107) | 1.93 (1.64 to 2.27) | 1.12 (0.96 to 1.32) |
Antibody geometric mean concentration (GMC) as measured by ELISA with their corresponding 95% CI immediately before and after the toddler dose for 7 common pneumococcal serotypes (Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| μg/mL | 13vPnC Before Toddler Dose | 7vPnC Before Toddler Dose | 13vPnC After Toddler Dose | 7vPnC After Toddler Dose |
|---|---|---|---|---|
| Common Serotypes-Serotype 4 (n=83,100,78,94) | 0.33 (0.28 to 0.40) | 0.48 (0.41 to 0.56) | 2.86 (2.31 to 3.55) | 4.09 (3.34 to 5.00) |
| Common Serotypes-Serotype 6B (n=82,98,78,93) | 0.84 (0.69 to 1.03) | 0.95 (0.77 to 1.18) | 11.03 (8.78 to 13.86) | 11.85 (9.63 to 14.56) |
| Common Serotypes-Serotype 9V (n=83,100,78,94) | 0.43 (0.37 to 0.51) | 0.43 (0.37 to 0.50) | 2.55 (2.15 to 3.02) | 2.75 (2.37 to 3.18) |
| Common Serotypes-Serotype 14 (n=83,100,78,93) | 1.59 (1.27 to 2.00) | 2.00 (1.66 to 2.41) | 7.68 (6.08 to 9.70) | 10.24 (8.23 to 12.74) |
| Common Serotypes-Serotype 18C (n=83,100,78,94) | 0.25 (0.22 to 0.30) | 0.40 (0.34 to 0.46) | 2.57 (2.08 to 3.18) | 4.08 (3.42 to 4.87) |
| Common Serotypes-Serotype 19F (n=82,100,78,93) | 0.81 (0.66 to 1.00) | 0.60 (0.49 to 0.72) | 6.34 (5.06 to 7.94) | 3.97 (3.26 to 4.85) |
| Common Serotypes-Serotype 23F (n=83,100,78,93) | 0.29 (0.24 to 0.36) | 0.38 (0.31 to 0.47) | 3.36 (2.70 to 4.18) | 4.79 (3.86 to 5.94) |
| Additional Serotypes-Serotype 1 (n=83,90,78,91) | 0.68 (0.56 to 0.82) | 0.04 (0.03 to 0.04) | 3.44 (2.79 to 4.23) | 0.03 (0.03 to 0.04) |
| Additional Serotypes-Serotype 3 (n=83,98,78,92) | 0.27 (0.23 to 0.32) | 0.09 (0.07 to 0.12) | 1.11 (0.94 to 1.33) | 0.10 (0.08 to 0.12) |
| Additional Serotypes-Serotype 5 (n=83,92,78,78) | 1.01 (0.87 to 1.18) | 0.40 (0.31 to 0.50) | 3.92 (3.27 to 4.69) | 0.56 (0.45 to 0.70) |
| Additional Serotypes-Serotype 6A (n=82,96,78,92) | 0.81 (0.68 to 0.96) | 0.27 (0.22 to 0.33) | 8.06 (6.60 to 9.85) | 1.68 (1.27 to 2.21) |
| Additional Serotypes-Serotype 7F (n=83,91,78,85) | 0.58 (0.50 to 0.67) | 0.04 (0.03 to 0.05) | 2.67 (2.26 to 3.16) | 0.05 (0.04 to 0.06) |
| Additional Serotypes-Serotype19A (n=83,100,78,93) | 0.85 (0.67 to 1.09) | 0.64 (0.52 to 0.79) | 5.60 (4.60 to 6.83) | 2.82 (2.32 to 3.41) |
Percentage of participants achieving predefined antibody threshold levels for Haemophilus Influenzae Type b (Hib) polyribosylribitol phosphate (PRP), Diphtheria Toxoid, Polio (Types 1, 2, and 3), Pertussis (filamentous hemagglutinin \[FHA\], Pertussis Toxoid, and Pertactin), Tetanus, and Hepatitis B with the corresponding 95% CI for each concomitant antigen are presented.
| Percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Hib (PRP) 0.15 μg/mL (n=84,87) | 89.29 (80.63 to 94.98) | 86.21 (77.15 to 92.66) |
| Hib (PRP) 1.0 μg/mL (n=84,87) | 70.24 (59.27 to 79.73) | 63.22 (52.20 to 73.31) |
| Diphtheria 0.01 IU/mL (n=38,48) | 100.00 (90.75 to 100.00) | 100.00 (92.60 to 100.00) |
| Diphtheria 0.1 IU/mL (n=38,48) | 100.00 (90.75 to 100.00) | 100.00 (92.60 to 100.00) |
| Tetanus 0.01 IU/mL (n=38,48) | 100.00 (90.75 to 100.00) | 100.00 (92.60 to 100.00) |
| Tetanus 0.1 IU/mL (n=38,48) | 100.00 (90.75 to 100.00) | 100.00 (92.60 to 100.00) |
| Polio Type 1 (antibody threshold ≥1:8) (n=61,64) | 100.00 (94.13 to 100.00) | 100.00 (94.40 to 100.00) |
| Polio Type 2 (antibody threshold ≥1:8) (n=61,64) | 98.36 (91.20 to 99.96) | 100.00 (9.40 to 100.00) |
| Polio Type 3 (antibody threshold ≥1:8) (n=61,63) | 98.36 (91.20 to 99.96) | 100.00 (94.31 to 100.00) |
| Hepatitis b 10 mIU/mL (n=38,48) | 100.00 (90.75 to 100.00) | 100.00 (92.60 to 100.00) |
| Pertussis - FHA 82.00 EU/MI (n=65,68) | 93.85 (84.99 to 98.30) | 95.59 (87.64 to 99.08) |
| Pertussis - Pertussis Toxoid 43.00 EU/mL (n=65,68) | 89.23 (79.06 to 95.56) | 95.59 (87.64 to 99.08) |
| Pertussis - Pertactin 18.00 EU/mL (n=65,68) | 96.92 (89.32 to 99.63) | 95.59 (87.64 to 99.08) |
| μg/mL | 13vPnC | 7vPnC |
|---|---|---|
| Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the Infant Series | 1.99 (1.34 to 2.97) | 1.64 (1.09 to 2.47) |
GMCs of anti-hepatitis B surface antigen (HBsAg) using a Food and Drug Administration (FDA) approved in vitro diagnostic kit are presented.
| milli International Units (mIU)/mL | 13vPnC | 7vPnC |
|---|---|---|
| Geometric Mean Antibody Concentration of Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series | 1257.74 (904.77 to 1748.42) | 1300.01 (976.91 to 1729.99) |
| IU/mL | 13vPnC | 7vPnC |
|---|---|---|
| Diphtheria Toxoid | 0.86 (0.65 to 1.14) | 1.04 (0.80 to 1.34) |
| Anti-Tetanus Toxoid | 0.93 (0.72 to 1.22) | 0.97 (0.73 to 1.28) |
| titer | 13vPnC | 7vPnC |
|---|---|---|
| Polio Type 1 (n=61,64) | 483.72 (352.52 to 663.75) | 479.79 (361.79 to 636.26) |
| Polio Type 2 (n=61,64) | 368.26 (250.75 to 540.84) | 403.45 (249.90 to 551.96) |
| Polio Type 3 (n=61,63) | 914.01 (638.80 to 1307.80) | 812.75 (577.32 to 1144.18) |
| EU/mL | 13vPnC | 7vPnC |
|---|---|---|
| Pertussis - filamentous hemagglutinin (FHA) | 207.85 (178.72 to 241.74) | 225.12 (191.97 to 264.01) |
| Pertussis - pertussis toxoid (PT) | 98.68 (82.89 to 117.49) | 96.58 (86.45 to 107.89) |
| Pertussis - pertactin | 141.23 (113.02 to 176.48) | 135.51 (107.13 to 171.41) |
Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| Percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Common Serotypes - Serotype 4 (n=30,33) | 96.67 (82.78 to 99.92) | 100.00 (89.42 to 100.00) |
| Common Serotypes - Serotype 6B (n=27,30) | 92.59 (75.71 to 99.09) | 93.33 (77.93 to 99.18) |
| Common Serotypes - Serotype 9V (n=27,27) | 100.00 (87.23 to 100.00) | 100.00 (87.23 to 100.00) |
| Common Serotypes - Serotype 14 (n=27,30) | 100.00 (87.23 to 100.00) | 100.00 (88.43 to 100.00) |
| Common Serotypes - Serotype 18C (n=27,30) | 100.00 (87.23 to 100.00) | 96.67 (82.78 to 99.92) |
| Common Serotypes - Serotype 19F (n=25,25) | 84.00 (63.92 to 95.46) | 80.00 (59.30 to 93.17) |
| Common Serotypes - Serotype 23F (n=27,26) | 92.59 (75.71 to 99.09) | 100.00 (86.77 to 100.00) |
| Additional Serotypes - Serotype 1 (n=30,32) | 83.33 (65.28 to 94.36) | 6.25 (0.77 to 20.81) |
| Additional Serotypes - Serotype 3 (n=25,29) | 80.00 (59.30 to 93.17) | 3.45 (0.09 to 17.76) |
| Additional Serotypes - Serotype 5 (n=30,33) | 100.00 (88.43 to 100.00) | 6.06 (0.74 to 20.23) |
| Additional Serotypes - Serotype 6A (n=25,29) | 96.00 (79.65 to 99.90) | 48.28 (29.45 to 67.47) |
| Additional Serotypes - Serotype 7F (n=22,24) | 100.00 (84.56 to 100.00) | 20.83 (7.13 to 42.15) |
| Additional Serotypes - Serotype 19A (n=22,24) | 77.27 (54.63 to 92.18) | 12.50 (2.66 to 32.36) |
Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were assessed. Results are reported for the serotypes with a determinate antibody titer.
| Percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Additional Serotypes - Serotype 6A (n=73,70) | 100.00 (95.1 to 100.00) | 90.0 (80.5 to 95.9) |
| Additional Serotypes - Serotype 19A (n=71,72) | 100.00 (94.9 to 100.00) | 51.4 (39.3 to 63.3) |
Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay (OPA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were assessed. Results are reported for the serotypes with a determinate antibody titer.
| titer | 13vPnC | 7vPnC |
|---|---|---|
| Additional Serotypes - Serotype 6A (n=73,70) | 2147.58 (1630.73 to 2828.23) | 599.90 (375.83 to 957.54) |
| Additional Serotypes - Serotype 19A (n=71,72) | 802.24 (633.92 to 1015.24) | 36.62 (21.09 to 63.59) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC Infant Series | — | 9/120 (7.5%) | 104/120 (86.7%) |
| 7vPnC Infant Series | — | 9/126 (7.1%) | 110/126 (87.3%) |
| 13vPnC Toddler Dose | — | 1/86 (1.2%) | 33/86 (38.4%) |
| 7vPnC Toddler Dose | — | 0/103 (0%) | 51/103 (49.5%) |
| 13vPnC 6-Month Follow-up | — | 4/86 (4.7%) | 20/86 (23.3%) |
| 7vPnC 6-Month Follow-up | — | 1/103 (1%) | 33/103 (32%) |
| Event | 13vPnC Infant Series | 7vPnC Infant Series | 13vPnC Toddler Dose | 7vPnC Toddler Dose | 13vPnC 6-Month Follow-up | 7vPnC 6-Month Follow-up |
|---|---|---|---|---|---|---|
| BronchiolitisInfections and infestations | 3/120 | 3/126 | 0/86 | 0/103 | 1/86 | 0/103 |
| Status asthmaticusRespiratory, thoracic and mediastinal disorders | 0/120 | 0/126 | 1/86 | 0/103 | 2/86 | 0/103 |
| DehydrationMetabolism and nutrition disorders | 2/120 | 2/126 | 0/86 | 0/103 | 0/86 | 0/103 |
| Asthma exacerbationRespiratory, thoracic and mediastinal disorders | 0/120 | 0/126 | 0/86 | 0/103 | 1/86 | 1/103 |
| Complex febrile seizureNervous system disorders | 0/120 | 0/126 | 0/86 | 0/103 | 1/86 | 0/103 |
| Fever of unknown originInfections and infestations | 1/120 | 0/126 | 0/86 | 0/103 | 1/86 | 0/103 |
| RSV positive bronchiolitisRespiratory, thoracic and mediastinal disorders | 0/120 | 1/126 | 0/86 | 0/103 | 1/86 | 0/103 |
| SeizureNervous system disorders | 0/120 | 0/126 | 0/86 | 0/103 | 1/86 | 0/103 |
| Viral URIInfections and infestations | 0/120 | 0/126 | 0/86 | 0/103 | 1/86 | 0/103 |
| Viral conjunctivitisInfections and infestations | 0/120 | 0/126 | 1/86 | 0/103 | 0/86 | 0/103 |
| Event | 13vPnC Infant Series | 7vPnC Infant Series | 13vPnC Toddler Dose | 7vPnC Toddler Dose | 13vPnC 6-Month Follow-up | 7vPnC 6-Month Follow-up |
|---|---|---|---|---|---|---|
| IrritabilityGeneral disorders | 79/118 | 88/124 | 33/85 | 48/101 | — | — |
| IrritabilityGeneral disorders | 69/110 | 67/118 | — | — | — | — |
| Increased sleepGeneral disorders | 67/119 | 67/124 | 24/86 | 44/101 | — | — |
| IrritabilityGeneral disorders | 55/107 | 63/117 | — | — | — | — |
| Upper respiratory tract infectionInfections and infestations | 57/120 | 65/126 | 8/86 | 10/103 | 5/86 | 12/103 |
| Increased sleepGeneral disorders | 47/111 | 55/118 | — | — | — | — |
| Tenderness (Any)Skin and subcutaneous tissue disorders | 41/119 | 54/124 | 19/85 | 30/101 | — | — |
| Increased sleepGeneral disorders | 37/107 | 48/117 | — | — | — | — |
| Tenderness (Any)Skin and subcutaneous tissue disorders | 31/110 | 43/118 | — | — | — | — |
| Otitis mediaInfections and infestations | 40/120 | 37/126 | 1/86 | 10/103 | 9/86 | 14/103 |
| Age Continuous(weeks) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Mean | 9.2 ± 1.4 | 9.1 ± 1.2 | 9.2 ± 1.3 |
| Sex: Female, Male(Participants) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Female | 58 | 59 | 117 |
| Male | 63 | 67 | 130 |
The record gives a start of Sep 2004 and a completion of May 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wyeth is now a wholly owned subsidiary of Pfizer →